Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of oral antidiabetic drugs, but they appear to have additional metabolic effects on circulating metabolites. At present, relevant studies have also proved that SGLT2 inhibition is related to the generation of diseases through metabolites.1,2 However, the impact of SGLT2 inhibition on cancer still needs to be explored. This study aimed to analyze the relationship between SGLT2 inhibition, blood metabolites, and lymphocytic leukemia by Mendelian randomization analysis.